Object Because of their size and lateral extension, total removal of nonfunctioning pituitary
adenomas (NFPAs) remains a challenge and postoperative tumor remnants are frequent …

Temozolomide, an orally administered alkylating agent, is used to treat malignant gliomas.
Recent reports also have documented its efficacy in the treatment of pituitary adenomas and …

Background Non-functioning pituitary adenomas (NFAs) are slow-growing tumours with
reported re-growth rates following surgical resection alone of up to 50% at 10 years …

The authors' object in this paper was to review the definition, epidemiology, biology,
resistance mechanisms, and treatment options for dopamine agonist–resistant …

Constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling
cascade occurs in a variety of human malignancies, where it sustains tumor cell proliferation …

Introduction: To describe the clinical imaging and hormonal characteristics and the natural
course of patients with clinically non-functioning pituitary adenomas (NFPAs) presenting at …

Clinically nonfunctioning pituitary tumors are common in tertiary endocrine practice.
Although it is widely accepted that patients with these adenomas require long-term …

Surgical removal of non-functioning pituitary adenoma (NFPA) is the first-choice therapeutic
option, but radical removal of the tumor cannot be accomplished in all patients. The best …

Neoplasms of the pituitary gland and sellar region constitute a unique crossroads in
medicine. The clinical manifestations of pituitary tumors are defined by their relationship with …

Nonfunctioning pituitary adenomas (NFPAs) are relatively common, accounting for 30% of
all pituitary adenomas; however, their pathogenesis remains enigmatic. To explore the …